Monoclonal Antibodies Partnering Terms & Agreements Reviewed in New Survey Report by CurrentPartnering22 Jan 2013 • by Natalie Aster
An understanding and access to the monoclonal antibodies partnering deals and agreements entered into by the worlds leading healthcare companies are provided in the new report “Monoclonal Antibody Partnering Terms and Agreements” by CurrentPartnering.
The report provides an understanding and analysis of how and why companies enter monoclonal antibody partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors monoclonal antibody technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report also includes polyclonal and antibody-drug conjugate deals and alliances.
Monoclonal Antibody Partnering Terms and Agreements
Published: December, 2012
Price: US$ 2,695.00
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.
This report contains over 1,000 links to online copies of actual monoclonal antibody deals and where available, contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
More information can be found in the report “Monoclonal Antibody Partnering Terms and Agreements” by CurrentPartnering.
To order the report or ask for sample pages contact firstname.lastname@example.org